Thanks Chiler, meant John (JK) not Sean in my previous post. So...

Thanks Chiler, meant John (JK) not Sean in my previous post. So I understand all that and I understand the raise thru IPO was primarily for tooling to increase manufacturing.

To clarify, if I do have a concern it is merely the ability to maximise the opportunity in the short term with the CV19 kits. NG has the rights to Europe only. If AT1 had the capacity to produce 10x the current capability I am sure we could sell it. I would be interested to hear how long it will take to scale up production capacity to take full advantage. Covid19 science is moving at light speed pace right now and I am hoping we still have the #1 product when production capacity ramps.